Investment Column: Oil finds back investment case for Tullow

Ark Therapeutics; Chime Communications


Our view: Buy

Share price: 758p (-54.5p)

Everyone knows that, despite the Government's best efforts, getting the banks to lend is like pulling teeth. Investors should sit up and take notice, therefore, when the likes of Royal Bank of Scotland, Barclays and Lloyds, among others, club together to arrange a new $2bn (£1.5bn) debt facility.

The grateful recipient is the FTSE 100-listed exploration and production company Tullow Oil, and looking at yesterday's results, it is easy to see why the bankers are happy to part with your cash. Pre-tax profits were up £110m and, to cap it all, the group has made "a major new discovery" of the black stuff at its fields in Uganda.

As the price of oil has fallen from its highs of $147 a barrel last July, Tullow's shares have risen. The group's stock price is up 64 per cent in the last quarter alone, which is all the more remarkable given that the company raised £402m from investors in a share placing in January. The fact that the debt financing is now in place also indicates that the group has sufficient cash to get its blue ribbon Jubilee project in Ghana off the ground.

Buyers would not be getting a cheap stock with Tullow Oil, and the group admits that the shares look expensive when compared with others in the sector. We would still be buyers given the confidence the market has in Tullow and its track record in finding oil. Analysts at Merrill Lynch argue indeed that the shares are good value trading "at a compelling discount to net asset value", making the company a "core holding in the E&P universe". We might not put it quite in those terms, but we agree with the sentiment. Buy.

Ark Therapeutics

Our view: Hold

Share price: 44p (-1.75p)

In one respect, investors would be mad to put their money into biotechnology companies. Almost all have lost value in the last year and with most merrily splashing the cash on research and development, which is necessary but seldom profitable, the prospect of dividends is limited.

At first glance the gene-based treatment group Ark Therapeutics is little different. The group said yesterday that it had recorded a sizeable loss, and there is nothing like the sniff of a dividend. Also much like others, it claims it is in a better position than most.

The chief executive, Nigel Parker, says that the stock's 39 per cent fall in the past year is due to wider market nervousness, and with £40m of net cash that takes Ark to the end of next year at least, the shares are undervalued.

Most of the analyst reaction yesterday was favourable, and with trials expected to start on what Mr Parker describes as a potential blockbuster drug, Trinam, which is designed to help those suffering from blocked veins and arteries, in the next year, the future could be rosy.

Biotech stocks tend to move on news, and investors are expecting an update soon on whether the group's brain cancer treatment, Cerepro, will get approval from European regulators. Watchers at KBC say that information is scant and that investors should sell. Mr Parker says that there is nothing to update, and moreover, nothing to worry about.

There will be a problem if the European approval is not forthcoming, and should the worst happen, recent share price gains will be lost. For that reason we would hold fire. Hold.

Chime Communications

Our view: Hold

Share price: 67p (+3.5p)

Like all others, public relations firms are suffering in the recession, despite the spinsters arguing that companies still need to get messages out.

At least Lord Bell, the chairman of Chime Communications, is honest enough to say that despite running one of the biggest PR groups, the recession is likely to hit his business at some point this year, even if there is little evidence of it yet.

Investors should take note, and although the shares were up yesterday on the back of impressive full-year results, which said that operating profits were up 15 per cent, we would be cautious about buying into a sector hit by clients cutting costs.

Watchers at KBC have the group on a buy, however, saying "on our forecast earnings of 18.3p... the stock trades on 3.5 times, which is in our view undemanding. Our target price of 80p would imply a still cautious 4.4 times".

Lord Bell says that once the economy improves, investors will be in clover. We do not disagree, but think it could be a while away. Hold.

Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
Buttoned up: Ryan Reynolds with Helen Mirren in ‘Woman in Gold’
filmFor every box-office smash in his Hollywood career, there's always been a misconceived let-down. Now he says it's time for a reboot
News
people
News
Actress Julianne Moore wins the Best Actress in a Leading Role Award for 'Still Alice' during the 87th Annual Academy Awards in Hollywood, California
people
Sport
Ross Barkley
footballPaul Scholes says it's time for the Everton playmaker to step up and seize the England No 10 shirt
News
'We will fix it': mice in the 1970s children’s programme Bagpuss
science
Life and Style
2 Karl Lagerfeld and Choupette
fashion
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Graduate Recruitment Resourcer

£20000 per annum + commission: SThree: Sthree have an exciting opportunity for...

Recruitment Genius: Telesales Executive - OTE £32,000+

£18000 - £32000 per annum: Recruitment Genius: A Telesales Executive is requir...

Ashdown Group: Marketing Manager - B2B, Corporate - City, London

£45000 - £50000 per annum + benefits : Ashdown Group: A highly successful, glo...

Neil Pavier: Commercial Analyst

£50,000 - £55,000: Neil Pavier: Are you a professionally qualified commercial ...

Day In a Page

War with Isis: Iraq declares victory in the battle for Tikrit - but militants make make ominous advances in neighbouring Syria's capital

War with Isis

Iraq declares victory in the battle for Tikrit - but militants make make ominous advances in neighbouring Syria
Scientists develop mechanical spring-loaded leg brace to improve walking

A spring in your step?

Scientists develop mechanical leg brace to help take a load off
Peter Ackroyd on Alfred Hitchcock: How London shaped the director's art and obsessions

Peter Ackroyd on Alfred Hitchcock

Ackroyd has devoted his literary career to chronicling the capital and its characters. He tells John Walsh why he chose the master of suspense as his latest subject
Ryan Reynolds interview: The actor is branching out with Nazi art-theft drama Woman in Gold

Ryan Reynolds branches out in Woman in Gold

For every box-office smash in Ryan Reynolds' Hollywood career, there's always been a misconceived let-down. It's time for a rethink and a reboot, the actor tells James Mottram
Why Robin Williams safeguarded himself against a morbid trend in advertising

Stars safeguard against morbid advertising

As film-makers and advertisers make increasing posthumous use of celebrities' images, some stars are finding new ways of ensuring that they rest in peace
The UK horticulture industry is facing a skills crisis - but Great Dixter aims to change all that

UK horticulture industry facing skills crisis

Great Dixter manor house in East Sussex is encouraging people to work in the industry by offering three scholarships a year to students, as well as generous placements
Hack Circus aims to turn the rule-abiding approach of TED talks on its head

Hack Circus: Technology, art and learning

Hack Circus aims to turn the rule-abiding approach of TED talks on its head. Rhodri Marsden meets mistress of ceremonies Leila Johnston
Sevenoaks is split over much-delayed decision on controversial grammar school annexe

Sevenoaks split over grammar school annexe

If Weald of Kent Grammar School is given the go-ahead for an annexe in leafy Sevenoaks, it will be the first selective state school to open in 50 years
10 best compact cameras

A look through the lens: 10 best compact cameras

If your smartphone won’t quite cut it, it’s time to invest in a new portable gadget
Paul Scholes column: Ross Barkley played well against Italy but he must build on that. His time to step up and seize that England No 10 shirt is now

Paul Scholes column

Ross Barkley played well against Italy but he must build on that. His time to step up and seize that England No 10 shirt is now
Why Michael Carrick is still proving an enigma for England

Why Carrick is still proving an enigma for England

Manchester United's talented midfielder has played international football for almost 14 years yet, frustratingly, has won only 32 caps, says Sam Wallace
Tracey Neville: The netball coach who is just as busy as her brothers, Gary and Phil

Tracey Neville is just as busy as her brothers, Gary and Phil

The former player on how she is finding time to coach both Manchester Thunder in the Superleague and England in this year's World Cup
General Election 2015: The masterminds behind the scenes

The masterminds behind the election

How do you get your party leader to embrace a message and then stick to it? By employing these people
Machine Gun America: The amusement park where teenagers go to shoot a huge range of automatic weapons

Machine Gun America

The amusement park where teenagers go to shoot a huge range of automatic weapons
The ethics of pet food: Why are we are so selective in how we show animals our love?

The ethics of pet food

Why are we are so selective in how we show animals our love?